NIIMBL Issues Roadmaps For Advancing Gene Therapy, Vaccine And Antibody Drug Conjugate Manufacturing
Executive Summary
A public/private manufacturing technology partnership has produced three roadmaps to help the biopharmaceutical industry navigate some of the regulatory and analytical hurdles in developing and manufacturing gene therapies, vaccines and antibody-drug conjugates. All three roadmaps cite a knowledge gap in the industry and the need for an adequately trained workforce.
You may also be interested in...
NIIMBL Seeks Advanced Biopharma Manufacturing Proposals To Fund
The public-private partnership has $5.5m for grants to develop continuous manufacturing methods, cell/gene therapy platforms and other biopharmaceutical manufacturing innovations.
Group Working To Close 'Standards Gaps' For Cell And Gene Therapies
A group is coordinating the development of standards for cell and gene therapies in a congressionally mandated effort that could help manufacturers produce these therapies at commercial scale.
Industry Roadmap Offers Route To Flexible, Low-Cost Biopharmaceutical Manufacturing
A biopharmaceutical industry consortium has released a roadmap to help the industry achieve the flexibility and cost reductions needed to deal with a changing business and manufacturing environment. The group is promoting the use of six enabling technologies.